Bincy Baby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bincy Baby has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- SooMin Park
School of Pharmacy, University of Waterloo, 10 Victoria St S A, Waterloo, ON, N2G 1C5, Canada, 1 (519) 888-4499 ext 21337
4 shared publications - Tejal Patel
School of Pharmacy, University of Waterloo, Waterloo, Canada
4 shared publications - Annette McKinnon
Patient Advisors Network, Toronto, ON, Canada
2 shared publications - Devine Samoth
School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
2 shared publications - Feng Chang
School of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada
2 shared publications - Ghada Elba
School of Pharmacy, University of Waterloo, Waterloo, ON N2G 1C5, Canada
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e88398
Performance-Based Usability of Medication Adherence Technologies Among Older Adults With Diverse Capabilities: Quantitative Study
Background: Medication adherence technologies (MATs) offer innovative solutions to support older adults in managing complex medication regimens, yet usability challenges can prevent their successful use. Older adults often face cognitive, physical, sensory, motivational, and environmental barriers, which can influence how they interact with these devices. Therefore, performance-based usability testing is essential for identifying usability issues. Objective: This study aimed to evaluate the performance-based usability and user experience of 13 MATs among older adults with diverse capabilities. Methods: A prospective mixed methods design was used, with 96 participants aged 60 years and older testing smart and electronic MATs using cognitive walkthroughs and predefined usability tasks without formal training to simulate first-use conditions. This manuscript focuses specifically on the performance-based usability metrics collected as part of the mixed methods study. Validated tools, including the Self-Medication Assessment Tool (SMAT), Daily Living Tasks Dependent on Vision (DLTV), Whisper Test, Self-Efficacy for Appropriate Medication Use Scale (SEAMS), and Martin and Park Environmental Demands (MPED) Questionnaire, were used to assess individual barriers. Poisson generalized estimating equations (GEE) was used to determine predictors of unassisted task success and error rates while accounting for repeated observations. Results: A total of 96 participants (mean age 75.1, SD 7.7, range 61‐95 y) were included, with 37.5% (36/96) male and 62.5% (60/96) female. Poisson GEE models identified significant predictors of unassisted task success rate, including cognitive score ( P <.001), physical score ( P <.001), vision score ( P <.001), motivational score ( P <.001), and lower environmental busyness ( P =.049). Female sex was associated with a 9% lower success rate ( P =.002). Predictors of total error rate included age ( P =.02), sex ( P ≤.001), physical score ( P ≤.001), vision score ( P =.004), DLTV vision score ( P =.01), MPED routine score (environmental; P =.05), and interaction between physical score and sex ( P =.004). Conclusions: Both device design and user characteristics strongly influence the usability of MATs. Performance-based evaluations provide actionable findings for user-centered design and selection, guiding manufacturers and health care providers toward developing and choosing accessible technologies that could improve medication adherence among older adults.
- 13 July 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e88398
Open AccessPerformance-Based Usability of Medication Adherence Technologies Among Older Adults With Diverse Capabilities: Quantitative Study
Background: Medication adherence technologies (MATs) offer innovative solutions to support older adults in managing complex medication regimens, yet usability challenges can prevent their successful use. Older adults often face cognitive, physical, sensory, motivational, and environmental barriers, which can influence how they interact with these devices. Therefore, performance-based usability testing is essential for identifying usability issues. Objective: This study aimed to evaluate the performance-based usability and user experience of 13 MATs among older adults with diverse capabilities. Methods: A prospective mixed methods design was used, with 96 participants aged 60 years and older testing smart and electronic MATs using cognitive walkthroughs and predefined usability tasks without formal training to simulate first-use conditions. This manuscript focuses specifically on the performance-based usability metrics collected as part of the mixed methods study. Validated tools, including the Self-Medication Assessment Tool (SMAT), Daily Living Tasks Dependent on Vision (DLTV), Whisper Test, Self-Efficacy for Appropriate Medication Use Scale (SEAMS), and Martin and Park Environmental Demands (MPED) Questionnaire, were used to assess individual barriers. Poisson generalized estimating equations (GEE) was used to determine predictors of unassisted task success and error rates while accounting for repeated observations. Results: A total of 96 participants (mean age 75.1, SD 7.7, range 61‐95 y) were included, with 37.5% (36/96) male and 62.5% (60/96) female. Poisson GEE models identified significant predictors of unassisted task success rate, including cognitive score ( P <.001), physical score ( P <.001), vision score ( P <.001), motivational score ( P <.001), and lower environmental busyness ( P =.049). Female sex was associated with a 9% lower success rate ( P =.002). Predictors of total error rate included age ( P =.02), sex ( P ≤.001), physical score ( P ≤.001), vision score ( P =.004), DLTV vision score ( P =.01), MPED routine score (environmental; P =.05), and interaction between physical score and sex ( P =.004). Conclusions: Both device design and user characteristics strongly influence the usability of MATs. Performance-based evaluations provide actionable findings for user-centered design and selection, guiding manufacturers and health care providers toward developing and choosing accessible technologies that could improve medication adherence among older adults.
- Open Access
- 8 April 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9 (1) , e84616
Personalized Predictive Model to Predict Subtask Success of Medication Adherence Technologies for Older Adults With Diverse Capabilities: Development and Internal Validation Study
Background: Older adults frequently experience cognitive, physical, sensory, motivational, and environmental barriers that affect medication management. Medication adherence technologies (MATs) can support adherence, but their usability varies widely depending on individual abilities and device features. Prior research has largely focused on overall adherence or user experience, providing limited insight into feature-level usability challenges. Objective: The aim of the study is to develop and internally validate a personalized predictive model to predict the success of MAT subtasks for older adults with diverse cognitive, physical, sensory, motivational, and environmental capabilities. Methods: A mixed methods approach was used, incorporating the assessment of impairments using various standardized questionnaires, measurement of usability metrics through cognitive walkthroughs, and one-on-one semistructured interviews. For this study, we used “subtasks” as the representative of features of the devices. A subtask is a discrete, individual action that forms part of a larger task, specifically designed to achieve a step in the overall process. Participants tested between 1 and 7 devices from a selection of 13 devices. The proportion of subtask success was taken as the outcome measure. Predictors included demographic, clinical, cognitive, physical, sensory, motivational, and environmental characteristics. Personalized predictive modeling using cosine similarity and generalized linear models were compared with nonpersonalized and naive models. Model performance was evaluated using mean square error (MSE) through cross-validation and held-out validation. Results: A total of 117 participants (mean age 74.6, SD 7.9 years) were recruited, including 96 participants for usability testing and 21 for the validation, all varying in cognitive, physical, sensory, motivational, and environmental abilities. Both personalized ( m =0.25) and nonpersonalized models ( m =1.0) outperformed naive predictions ( m =1.21), demonstrating that subtask-level success can be predicted using routinely measurable demographic and functional characteristics. During cross-validation, personalized models achieved optimal performance at a matching proportion of m =0.25, with MSEs lower than those observed at higher matching levels, although differences compared with nonpersonalized models were not statistically significant (Self-Medication Assessment Tool [SMAT]: P =.50; Daily Living Tasks Dependent on Vision [DLTV]: P =.43). In the held-out validation cohort, personalized models achieved MSEs of 0.89 (SMAT-based) and 1.16 (DLTV-based) at m=0.20, whereas nonpersonalized models demonstrated better performance with MSEs of 0.726 (SMAT-based) and 0.815 (DLTV-based). Models incorporating performance-based vision measures (SMAT-based) consistently outperformed those using self-reported vision scores (DLTV-based) across both personalized and nonpersonalized settings. Conclusions: This study demonstrates the feasibility of predicting subtask success of MATs in older adults. While personalization showed limited added benefit in this dataset, the subtask-focused model provides clinically meaningful insights to support evidence-informed selection of medication technologies, reduce usability-related medication errors, and improve adherence outcomes.
- 8 April 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9 (1) , e84616
Open AccessPersonalized Predictive Model to Predict Subtask Success of Medication Adherence Technologies for Older Adults With Diverse Capabilities: Development and Internal Validation Study
Background: Older adults frequently experience cognitive, physical, sensory, motivational, and environmental barriers that affect medication management. Medication adherence technologies (MATs) can support adherence, but their usability varies widely depending on individual abilities and device features. Prior research has largely focused on overall adherence or user experience, providing limited insight into feature-level usability challenges. Objective: The aim of the study is to develop and internally validate a personalized predictive model to predict the success of MAT subtasks for older adults with diverse cognitive, physical, sensory, motivational, and environmental capabilities. Methods: A mixed methods approach was used, incorporating the assessment of impairments using various standardized questionnaires, measurement of usability metrics through cognitive walkthroughs, and one-on-one semistructured interviews. For this study, we used “subtasks” as the representative of features of the devices. A subtask is a discrete, individual action that forms part of a larger task, specifically designed to achieve a step in the overall process. Participants tested between 1 and 7 devices from a selection of 13 devices. The proportion of subtask success was taken as the outcome measure. Predictors included demographic, clinical, cognitive, physical, sensory, motivational, and environmental characteristics. Personalized predictive modeling using cosine similarity and generalized linear models were compared with nonpersonalized and naive models. Model performance was evaluated using mean square error (MSE) through cross-validation and held-out validation. Results: A total of 117 participants (mean age 74.6, SD 7.9 years) were recruited, including 96 participants for usability testing and 21 for the validation, all varying in cognitive, physical, sensory, motivational, and environmental abilities. Both personalized ( m =0.25) and nonpersonalized models ( m =1.0) outperformed naive predictions ( m =1.21), demonstrating that subtask-level success can be predicted using routinely measurable demographic and functional characteristics. During cross-validation, personalized models achieved optimal performance at a matching proportion of m =0.25, with MSEs lower than those observed at higher matching levels, although differences compared with nonpersonalized models were not statistically significant (Self-Medication Assessment Tool [SMAT]: P =.50; Daily Living Tasks Dependent on Vision [DLTV]: P =.43). In the held-out validation cohort, personalized models achieved MSEs of 0.89 (SMAT-based) and 1.16 (DLTV-based) at m=0.20, whereas nonpersonalized models demonstrated better performance with MSEs of 0.726 (SMAT-based) and 0.815 (DLTV-based). Models incorporating performance-based vision measures (SMAT-based) consistently outperformed those using self-reported vision scores (DLTV-based) across both personalized and nonpersonalized settings. Conclusions: This study demonstrates the feasibility of predicting subtask success of MATs in older adults. While personalization showed limited added benefit in this dataset, the subtask-focused model provides clinically meaningful insights to support evidence-informed selection of medication technologies, reduce usability-related medication errors, and improve adherence outcomes.
- Open Access
- 19 December 2023
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 6 (1) , e50990
Key Features of Smart Medication Adherence Products: Updated Scoping Review
Background: Older adults often face challenges in self-managing their medication owing to physical and cognitive limitations, complex medication regimens, and packaging of medications. Emerging smart medication dispensing and adherence products (SMAPs) offer the options of automated dispensing, tracking medication intake in real time, and reminders and notifications. A 2021 review identified 51 SMAPs owing to the rapid influx of digital technology; an update to this review is required. Objective: This review aims to identify new products and summarize and compare the key features of SMAPs. Methods: Gray and published literature and videos were searched using Google, YouTube, PubMed, Embase, and Scopus. The first 10 pages of Google and the first 100 results of YouTube were screened using 4 and 5 keyword searches, respectively. SMAPs were included if they were able to store and allowed for the dispensation of medications, tracked real-time medication intake data, and could automatically analyze data. Products were excluded if they were stand-alone software applications, not marketed in English, not for in-home use, or only used in clinical trials. In total, 5 researchers independently screened and extracted the data. Results: This review identified 114 SMAPs, including 80 (70.2%) marketed and 34 (29.8%) prototypes, grouped into 15 types. Among the marketed products, 68% (54/80) were available for consumer purchase. Of these products, 26% (14/54) were available worldwide and 78% (42/54) were available in North America. There was variability in the hardware, software, data collection and management features, and cost of the products. Examples of hardware features include battery life, medication storage capacity, availability of types and number of alarms, locking features, and additional technology required for use of the product, whereas software features included reminder and notification capabilities and availability of manufacturer support. Data capture methods included the availability of sensors to record the use of the product and data-syncing capabilities with cloud storage with short-range communications. Data were accessible to users via mobile apps or web-based portals. Some SMAPs provided data security assurance with secure log-ins (use of personal identification numbers or facial recognition), whereas other SMAPs provided data through registered email addresses. Although some SMAPs were available at set prices or free of cost to end users, the cost of other products varied based on availability, shipping fees, and subscription fees. Conclusions: An expanding market for SMAPs with features specific to at-home patient use is emerging. Health care professionals can use these features to select and suggest products that meet their patients’ unique requirements.
- 19 December 2023
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 6 (1) , e50990
Open AccessKey Features of Smart Medication Adherence Products: Updated Scoping Review
Background: Older adults often face challenges in self-managing their medication owing to physical and cognitive limitations, complex medication regimens, and packaging of medications. Emerging smart medication dispensing and adherence products (SMAPs) offer the options of automated dispensing, tracking medication intake in real time, and reminders and notifications. A 2021 review identified 51 SMAPs owing to the rapid influx of digital technology; an update to this review is required. Objective: This review aims to identify new products and summarize and compare the key features of SMAPs. Methods: Gray and published literature and videos were searched using Google, YouTube, PubMed, Embase, and Scopus. The first 10 pages of Google and the first 100 results of YouTube were screened using 4 and 5 keyword searches, respectively. SMAPs were included if they were able to store and allowed for the dispensation of medications, tracked real-time medication intake data, and could automatically analyze data. Products were excluded if they were stand-alone software applications, not marketed in English, not for in-home use, or only used in clinical trials. In total, 5 researchers independently screened and extracted the data. Results: This review identified 114 SMAPs, including 80 (70.2%) marketed and 34 (29.8%) prototypes, grouped into 15 types. Among the marketed products, 68% (54/80) were available for consumer purchase. Of these products, 26% (14/54) were available worldwide and 78% (42/54) were available in North America. There was variability in the hardware, software, data collection and management features, and cost of the products. Examples of hardware features include battery life, medication storage capacity, availability of types and number of alarms, locking features, and additional technology required for use of the product, whereas software features included reminder and notification capabilities and availability of manufacturer support. Data capture methods included the availability of sensors to record the use of the product and data-syncing capabilities with cloud storage with short-range communications. Data were accessible to users via mobile apps or web-based portals. Some SMAPs provided data security assurance with secure log-ins (use of personal identification numbers or facial recognition), whereas other SMAPs provided data through registered email addresses. Although some SMAPs were available at set prices or free of cost to end users, the cost of other products varied based on availability, shipping fees, and subscription fees. Conclusions: An expanding market for SMAPs with features specific to at-home patient use is emerging. Health care professionals can use these features to select and suggest products that meet their patients’ unique requirements.
- Open Access
- 20 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Key Features of Smart Medication Adherence Products: Updated Scoping Review (Preprint)
BACKGROUND Older adults often face challenges in self-managing their medication owing to physical and cognitive limitations, complex medication regimens, and packaging of medications. Emerging smart medication dispensing and adherence products (SMAPs) offer the options of automated dispensing, tracking medication intake in real time, and reminders and notifications. A 2021 review identified 51 SMAPs owing to the rapid influx of digital technology; an update to this review is required. OBJECTIVE This review aims to identify new products and summarize and compare the key features of SMAPs. METHODS Gray and published literature and videos were searched using Google, YouTube, PubMed, Embase, and Scopus. The first 10 pages of Google and the first 100 results of YouTube were screened using 4 and 5 keyword searches, respectively. SMAPs were included if they were able to store and allowed for the dispensation of medications, tracked real-time medication intake data, and could automatically analyze data. Products were excluded if they were stand-alone software applications, not marketed in English, not for in-home use, or only used in clinical trials. In total, 5 researchers independently screened and extracted the data. RESULTS This review identified 114 SMAPs, including 80 (70.2%) marketed and 34 (29.8%) prototypes, grouped into 15 types. Among the marketed products, 68% (54/80) were available for consumer purchase. Of these products, 26% (14/54) were available worldwide and 78% (42/54) were available in North America. There was variability in the hardware, software, data collection and management features, and cost of the products. Examples of hardware features include battery life, medication storage capacity, availability of types and number of alarms, locking features, and additional technology required for use of the product, whereas software features included reminder and notification capabilities and availability of manufacturer support. Data capture methods included the availability of sensors to record the use of the product and data-syncing capabilities with cloud storage with short-range communications. Data were accessible to users via mobile apps or web-based portals. Some SMAPs provided data security assurance with secure log-ins (use of personal identification numbers or facial recognition), whereas other SMAPs provided data through registered email addresses. Although some SMAPs were available at set prices or free of cost to end users, the cost of other products varied based on availability, shipping fees, and subscription fees. CONCLUSIONS An expanding market for SMAPs with features specific to at-home patient use is emerging. Health care professionals can use these features to select and suggest products that meet their patients’ unique requirements.
- 20 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessKey Features of Smart Medication Adherence Products: Updated Scoping Review (Preprint)
BACKGROUND Older adults often face challenges in self-managing their medication owing to physical and cognitive limitations, complex medication regimens, and packaging of medications. Emerging smart medication dispensing and adherence products (SMAPs) offer the options of automated dispensing, tracking medication intake in real time, and reminders and notifications. A 2021 review identified 51 SMAPs owing to the rapid influx of digital technology; an update to this review is required. OBJECTIVE This review aims to identify new products and summarize and compare the key features of SMAPs. METHODS Gray and published literature and videos were searched using Google, YouTube, PubMed, Embase, and Scopus. The first 10 pages of Google and the first 100 results of YouTube were screened using 4 and 5 keyword searches, respectively. SMAPs were included if they were able to store and allowed for the dispensation of medications, tracked real-time medication intake data, and could automatically analyze data. Products were excluded if they were stand-alone software applications, not marketed in English, not for in-home use, or only used in clinical trials. In total, 5 researchers independently screened and extracted the data. RESULTS This review identified 114 SMAPs, including 80 (70.2%) marketed and 34 (29.8%) prototypes, grouped into 15 types. Among the marketed products, 68% (54/80) were available for consumer purchase. Of these products, 26% (14/54) were available worldwide and 78% (42/54) were available in North America. There was variability in the hardware, software, data collection and management features, and cost of the products. Examples of hardware features include battery life, medication storage capacity, availability of types and number of alarms, locking features, and additional technology required for use of the product, whereas software features included reminder and notification capabilities and availability of manufacturer support. Data capture methods included the availability of sensors to record the use of the product and data-syncing capabilities with cloud storage with short-range communications. Data were accessible to users via mobile apps or web-based portals. Some SMAPs provided data security assurance with secure log-ins (use of personal identification numbers or facial recognition), whereas other SMAPs provided data through registered email addresses. Although some SMAPs were available at set prices or free of cost to end users, the cost of other products varied based on availability, shipping fees, and subscription fees. CONCLUSIONS An expanding market for SMAPs with features specific to at-home patient use is emerging. Health care professionals can use these features to select and suggest products that meet their patients’ unique requirements.